

You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
Antibody Characterization Report for Sequestosome-1
Antibody Characterization Report for Sequestosome-1
Head to head comparison of available commercial antibodies against Sequestosome-1 by immunoblot (Western blot), immunoprecipitation and immunofluorescence. The workflow and data collected in this study was used to create an article published on F1000, DOI: 10.12688/f1000research.132628.1. This work is part of the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities - the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.
antibody characterization, EBI3-associated protein of 60 kDa, p60, Q13501, p62, Ubiquitin-binding protein p62, Phosphotyrosine-independent ligand for the Lck SH2 domain of 62 kDa, Sequestosome-1, antibody validation, EBIAP, Amyotrophic lateral sclerosis, ALS-RAP, sqstm1
antibody characterization, EBI3-associated protein of 60 kDa, p60, Q13501, p62, Ubiquitin-binding protein p62, Phosphotyrosine-independent ligand for the Lck SH2 domain of 62 kDa, Sequestosome-1, antibody validation, EBIAP, Amyotrophic lateral sclerosis, ALS-RAP, sqstm1
18 Research products, page 1 of 2
- 2022IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2023IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average visibility views 360 download downloads 270 citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average Powered byBIP!
- 360views270downloads



Head to head comparison of available commercial antibodies against Sequestosome-1 by immunoblot (Western blot), immunoprecipitation and immunofluorescence. The workflow and data collected in this study was used to create an article published on F1000, DOI: 10.12688/f1000research.132628.1. This work is part of the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities - the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.